Company Timeline

Company Timeline

March 1997	Tony J. Morris founds Neotonus Inc., a venture-funded corporation whose mission is to provide cost-effective, non-invasive healthcare solutions.
March 1997	Neotonus develops Extracorporeal Magnetic Innervation (ExMI™), a medical technology for the treatment and management of neurological and neuromuscular disorders. Phase I urinary incontinence clinical trial begins.
March 1998	U.S. Patent & Trademark Office issues first patent to Neotonus.
April 1998	Pivotal study using ExMI for treatment of refractory depression begins.
June 1998	U.S. Food and Drug Administration clears ExMI for the treatment of stress, urge and mixed urinary incontinence in women.
June 1998	Neotonus begins to manufacture and market the NeoControl® Pelvic Floor Therapy System, the first product to utilize ExMI technology.
May 1999	Data from clinical studies at the Cleveland Clinic and sites in Chicago, Philadelphia and Orlando indicate that 50 percent of women who completed six weeks of NeoControl therapy reported being "completely dry" and an additional 30 percent reported "significant improvement" in their conditions.
November 1999	The U.S. Patent & Trademark Office determines that a patent application relating to the company's transcranial magnetic brain stimulator medical treatment contains "patentable and allowable subject matter." The decision clears the way for issuance of a patent on Neotonus' landmark technology, which can be used for the non-invasive treatment of depression, epilepsy, Alzheimer's disease and a host of other neurological disorders.
December 1999	Neotonus places more than 150 NeoControl Pelvic Floor Therapy Systems in urology and obstetrics/gynecology practices throughout the United States and 10 other countries.
December 1999	Neotonus moves to new office to accomodate growth.
January 2000	Doctors deliver more than 20,000 NeoControl treatments to American women suffering with incontinence.
January 2000	Neotonus launches the first study using new pulsed magnetic therapy as a non-invasive treatment for urinary incontinence among men who have undergone radical prostatectomy for prostate cancer. The study offers hope to the 330,000 men who are diagnosed with prostate cancer each year, many of whom will require prostate surgery, the leading cause of incontinence in men.
January 2000	Neotonus restructures to accomodate growth of clinical applications.
December 2001	AMA established CPT category 3 code for NeoControl Pelvic Floor Therapy (0029T).
April 2002	Empire Blue Cross Blue Shield includes magnetic pelvic floor stimulation in its policy statement.
February 2003	Georgia Medicare provides a coverage policy for NeoControl Pelvic Therapy System, extending coverage to millions of incontinence patients in Georgia.
September 2003	Neotonus launches a Global Initiative, creating a vast international distributors network to expand its presence overseas. To date, 42 countries are represented around the world.
June 2004	Neotonus continues rigorous negotiations with the American Medical Association (AMA) and the American Urological Association (AUA) to obtain a CPT category 1 code for NeoControl Pelvic Floor Therapy and nationwide third-party reimbursement.
April 2005	Neotonus enters its 47th country, while surpassing the 1 million treatment mark. The first hearing in an anti-trust suit against the AMA and AUA commences.